Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a Healthcare company (Biotechnology) with a market capitalization of $5.9B. The Maz Rating grades it against the other companies in its sector.
Ligand Pharmaceuticals Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $293.81, Ligand Pharmaceuticals Incorporated trades at 112.7x trailing earnings, 23.0x sales and 6.1x book value, with an EV/EBITDA of 86.5. Over the last twelve months it generated about $255M of revenue and $52M of net income. It runs an operating margin of 11.9% and a net margin of 20.3%. It shows return on equity of 5.2%, return on invested capital of 1.3% and a free cash flow yield of 1.5%. On the balance sheet: a debt-to-equity ratio of 1.20 and a current ratio of 1.22. Over the past 52 weeks the share price ranged from $175.89 to $326.63, with a beta of 1.03.
Ligand Pharmaceuticals Incorporated does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 13 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Ligand Pharmaceuticals Incorporated (LGND) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 18.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.88% / 30% · Interest income / Revenue 3.29% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 18.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.49% / 33% · Receivables / Mkt Cap (36m) 1.80% / 49% · Interest income / Revenue 3.29% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 18.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.49% / 33.33% · Receivables / Mkt Cap (24m) 1.80% / 33.33% · Interest income / Revenue 3.29% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 41.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 44.1% / 33.33% · Receivables / Avg Assets (4Q) 3.90% / 33.33% · Interest income / Revenue 3.29% / 5% | Fail |
| FTSE | Debt / Total Assets 50.4% / 33.33% · (Cash+ST Inv) / Total Assets 20.0% / 33.33% · (Cash+Recv) / Total Assets 24.8% / 33.33% · Interest income / Revenue 3.29% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Ligand Pharmaceuticals Incorporated (LGND) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Ligand Pharmaceuticals Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.29% of each dividend: Ligand Pharmaceuticals Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.